Softhaler

Softhaler® is a next-generation soft-mist inhalation device platform that uses differentiated technology to deliver propellant-free liquid-based formulation to the lung.

Effective Delivery, Multiple Applications

The Softhaler® device mechanically converts the liquid formulation into an ultra-fine mist to deliver the medication to the lungs more effectively than other types of inhalers, leading to better lung delivery and less deposition in the mouth or at the back of the throat.

Both smaller chemical API molecules and larger complex formulations can be delivered by the Softhaler® device. This leads to a wide variety of applications in generic products, as well as new combinations of existing APIs, NCEs and biologics, making the Softhaler® a true platform device.

• The soft-mist inhalation (SMI) device platform will be one of the US approved SMI products with opportunities as first-to-market generic solution and partnerships with novel biopharma.
• It provides an Opportunity to disrupt a $43bn inhalation device market with limited innovation and competition by launching both generic and new chemical entity SMI products to change the treatment paradigm in asthma, COPD and beyond.
• Platform is supported by a unique well-invested end to end customizable supply chain to bring products and partners’ products through from early development to the market.
• It has a clear path to commercializing advanced pipeline of Generic and innovative products.

Key Benefits of Softhaler® Over Other Inhalers

Convenience of Administration

• Softhaler® eliminates the need for a face mask or spacer, significantly reducing administration time compared to nebulizers while delivering a similar lung dosage.
• It requires no hand-breath coordination or special inhalation effort, thanks to its slow velocity and long-lasting mist. This makes it particularly advantageous for patients with impaired lung function.

High Lung Deposition

With its fine droplets and low spray velocity, Softhaler® effectively delivers medication deeper into the lungs, enhancing dose delivery efficiency.

• This improved lung deposition allows for lower dosing requirements, which can reduce the side effects associated with the drug.
• The gentle soft mist delivery minimizes the risk of inducing coughs, a common side effect of dry powder inhalers (DP|s).

Environmental Friendliness

• Softhaler® contains no propellants, making it a more environmentally friendly alternative to pressurized metered-dose inhalers (pMDIs).
• As a purely mechanical device, it eliminates the need for battery disposal.

Furthermore, InvoX is committed to advancing the next generation of Softhaler®, aiming to provide additional benefits for patients, including:

• A digital dosing counter for compliance tracking.
• A safety lock to restrict dosing within specified periods.
• Dosing guidance for complex regimens, such as titration.